Motor behavior abnormalities in drug-naïve patients with schizophrenia spectrum disorders†
Corresponding Author
Victor Peralta MD, PhD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Psychiatric Unit, Virgen del Camino Hospital, Irunlarrea 4, Pamplona 31008, SpainSearch for more papers by this authorMaria S. Campos MD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Search for more papers by this authorElena García De Jalón MD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Search for more papers by this authorManuel J. Cuesta MD, PhD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Search for more papers by this authorCorresponding Author
Victor Peralta MD, PhD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Psychiatric Unit, Virgen del Camino Hospital, Irunlarrea 4, Pamplona 31008, SpainSearch for more papers by this authorMaria S. Campos MD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Search for more papers by this authorElena García De Jalón MD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Search for more papers by this authorManuel J. Cuesta MD, PhD
Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain
Search for more papers by this authorPotential conflict of interest: Nothing to report.
Abstract
Prevalence and correlates of primary motor abnormalities in schizophrenia are presently ill defined. This study was aimed at examining the prevalence, syndromic structure, external correlates, and response to antipsychotic medication of a broad array of primary motor abnormalities. Two-hundred antipsychotic-naive patients with schizophrenia spectrum disorders were examined for motor abnormalities using the Modified Rogers Scale. Thirty-one motor signs were subjected to factor analysis, and the resulting factors examined for association with a number of risk factors, clinical and psychopathological variables. One-hundred and eighty-nine patients were reassessed for motor abnormalities after completing a 4-week trial with antipsychotic medication. Prevalence rates for at least one motor sign and syndrome at baseline were 66% and 40%, respectively. Motor signs clustered together into seven clinically interpretable factors: abnormal involuntary movements, hypokinesia, retarded catatonia, echo-phenomena, excited catatonia, catalepsy, and parkinsonism. All motor domains but parkinsonism were inter-related. Abnormal involuntary movements were associated with variables indicating both neurodevelopmental dysfunction and illness severity, and most motor domains were closely related to negative or disorganization symptoms. Change scores in motor domains after treatment with antipsychotic medication indicated improvement for abnormal involuntary movements, hypokinesia, retarded catatonia, excited catatonia and echophenomena, and worsening for parkinsonism. It is concluded that primary motor dysfunction is a prevalent and heterogeneous condition of schizophrenia. Motor abnormalities segregate into various syndromes, which have different clinical correlates and a differential response pattern to antipsychotic medication. It is hypothesized that the existence of a differential dopaminergic dysfunction in the nigroestriatal circuitry is responsible for the generation of those motor domains that improve and worsen with antipsychotic drugs. © 2010 Movement Disorder Society
REFERENCES
- 1 Rogers D. The motor disorders of severe psychiatric illness: a conflict of paradigms. Br J Psychiatry 1985; 147: 221–232.
- 2 Kahlbaum KL. Die Katatonie oder das Spannungirresein. Berlin: Verlag August Hirschwald; 1874.
- 3 Kraepelin E,Barklay RM. Dementia Praecox and Paraphrenia, Translated by Barklay RM. Edinburgh: Livingstone; 1913.
- 4 Bleuler E,Zinkin J. Dementia Praecox or the group of Schizophrenias, Translated by Zinkin J. New York, NY: International University Press; 1911.
- 5 Morrison JR. Changes in subtype diagnosis of schizophrenia: 1920–1966. Am J Psychiatry 1974; 131: 674–677.
- 6 Manschreck TC. Disturbed voluntary motor activity in schizophrenic disorder. Psychol Med 1982; 12: 73–84.
- 7 Gelenberg AJ,Mandel MR. Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry 1977; 34: 947–950.
- 8 Ortí-Pareja M,Jímenez-Jímenez JJ,Vázquez A, et al. Drug-induced tardive syndromes. Parkinson Rel Dis 1999; 5: 59–65.
- 9 Janno S,Holi M,Tuisju K, et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161: 160–163.
- 10 Whitty PF,Owoeye O,Waddington J. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr Bull 2009; 35: 415–424.
- 11 Pappa S,Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009; 39: 1065–1076.
- 12 Bush G,Petrides G,Francis A. Catatonia and other motor syndromes in a chronically hospitalized psychiatric population. Schizophr Res 1997; 27: 83–92.
- 13 Peralta V,Cuesta MJ. Negative, parkinsonian and catatonic symptoms in schizophrenia: a conflict of paradigms revisited. Schizophr Res 1999; 40: 245–253.
- 14 Peralta V,Campos MS,Garcia De Jalon E, et al. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone or olanzapine. Prim Care Companion J Clin Psychiatry [Epub ahead of print]; doi:10.4088/pcc09m00799gry.
- 15 Peralta V,Cuesta MJ. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 2001; 49: 269–285.
- 16 Ungvari GS,Caroff SN,Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull, [Epub ahead of print]; doi:10.1093/schbul/sbp105
- 17 Graybel AM. The basal ganglia and cognitive pattern generators. Schizophr Bull 1997; 23: 459–467.
- 18 Shenton ME,Dickey CC,Frumin M, et al. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1–52.
- 19 Howes OD,Montgomery AJ,Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13–20.
- 20 American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth ed. Washington, D.C.: American Psychiatric Association; 1994.
- 21 Andreasen NC,Flaum M,Arndt S. The comprehensive assessment of symptoms and diagnosis. An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49: 615–623.
- 22 Harris JG. Abbreviated form of the Phillips rating scale of premorbid adjustment in schizophrenia. J Abnorm Psychol 1975; 84: 129–137.
- 23
Andreasen NC,Endicott J,Spitzer RL, et al.
The family history method using diagnostic criteria.
Arch Gen Psychiatry
1977;
47:
615–621.
10.1001/archpsyc.1990.01810190015002 Google Scholar
- 24 Perkins DO,Leserman J,Jarskog LF, et al. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res 2000; 44: 1–10.
- 25 Guy W. The efficacy index. ECDEU assessment manual for psychopharmacology. US Washington, DC: Government Printing Office; 1976.
- 26 Mcneil TF,Sjöström K. The McNeil-Sjöström scale for obstetric complications. Malmö, Sweden: Lund University Department of Psychiatry; 1995.
- 27 Lund CE,Mortimer AM,Rogers D, et al. Motor, volitional and behavioural disorders in schizophrenia, Part 1: assessment using the Modified Rogers Scale. Br J Psychiatry 1991; 158: 323–327.
- 28 Mckenna PJ,Lund C,Mortimer A, et al. Motor, volitional and behavioral disorders in schizophrenia, Part 2: the ‘conflict of paradigms’ hypothesis. Br J Psychiatry 1991; 158: 328–336.
- 29 Starkstein SE,Petracca G,Tesón A, et al. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiat 1996; 60: 326–332.
- 30 Peralta V,Cuesta MJ. Motor features in psychotic disorders. I. Factor structure and clinical correlates. Schizophr Res 2001; 47: 107–116.
- 31 Northoff G,Koch A,Wenke J,Eckert J, et al. Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms. Mov Disord 1999; 14: 404–416.
- 32 Simpson GM,Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiat Scand 1970; 212: ( suppl. 44) 11–19.
- 33 Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–676.
- 34 Marder SR,Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–835.
- 35 Chouinard G,Jones B,Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40.
- 36 Honer WG,Kopala LC,Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic-exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmachol 2005; 19: 277–285.
- 37 Krüger S,Bagby RM,Höffler J, et al. Factor analysis of the catatonia rating scale and catatonic symptom distribution across four diagnostic groups. Comp Psychiatry 2003; 44: 472–482.
- 38 Ungvary GS,Goggings W,Leung SK, et al. Schizophrenia with prominent catatonic features (‘catatonic schizophrenia’). II. Factor analysis of the catatonic syndrome. Prog Neuro-Psychopharmacol Biol Psychiatry 2007; 31: 462–468.
- 39 Fenton WS,Wyatt RJ,Mcglashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994; 51: 643–650.
- 40 Peralta V,Cuesta MJ,Serrano JF,Martinez-Larrea JA. Classification issues in catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251: ( Suppl 1) 14–16.
- 41 Obeso JA,Rodríguez-Oroz MC,Rodríguez M, et al. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Psysiol Sci 2002; 17: 51–55.
- 42 Kapur S,Mizrahi R,Li M. From dopamine to salience to psychosis: linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005; 79: 59–68.
- 43 Laruelle M,Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13: 358–371.
- 44 Hietala J,Syvälahti E,Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346: 1130–1131.
- 45 Mateos JJ,Lomeña F,Parellada E, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmachology 2007; 191: 805–811.
- 46 Schmitt GJE,Meisenzahl EM,Frodl T, et al. Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [123I]IBZM SPECT. Psychiatry Res Neuroimaging 2009; 173: 183–189.
- 47 Dao-Castellana MH,Paillere-Martinot ML,Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenia patients. Schizophr Res 1997; 23: 167–174.
- 48 Elkashef AM,Doudet D,Bryant T, et al. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000; 100: 1–11.
- 49 Utter AM,Basso MA. The basal ganglia: an overview of circuits and function. Neurosci Biobehav Rev 2008; 32: 333–342.
- 50 Andreasen NC,Paradiso S,O'leary DS. ‘Cognitive dysmetria’ as integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?. Schizophr Bull 1998; 24: 203–218.
- 51 Mehler-Wex C,Riederer P,Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit disorder. Neurotox Res 2006; 10: 167–179.